AS 1411
Based on 2 publication(s) in Google Scholar
AS 1411 (AGRO-100) is an oligonucleotide aptamer targeting nucleoproteins. AS 1411 inhibits tumor cell proliferation by affecting the activity of nucleoprotein-containing complexes and can be used as a carrier to precisely deliver nanoparticles, oligonucleotides and small molecules to cancer cells. AS 1411 reduces PRMT5 expression to inhibit tumor growth in DU145 prostate cancer cells. AS 1411 works by blocking the binding of nucleoproteins to bcl-2 mRNA in MCF-7 breast cancer cells. AS 1411-coupled Jin nanospheres can inhibit breast cancer cell proliferation in vitro and in mouse models, has the ability to cross the blood-brain barrier with low tissue toxicity.
For research use only. We do not sell to patients.
- Purity: 99.52%
- CAS No.: 301636-59-9
- Molecular Weight:8272.31
-
Storage:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) AS 1411
MoreAll Histone Methyltransferase Isoforms
More
Biological Activity
|
Bcl-2 |
AS 1411 (10 μM, 0-48 h) alters the nuclear localization of PRMT5 in DU145 cells[1].
AS 1411 (10 μM, 24 h) reduces PRMT5 expression and increases the expression of cyclin E2 and ST7[1].
AS 1411 (0-20 μM, 0-96 h) inhibits MCF-7 cell proliferation without affecting MCF-10A cells[2].
AS 1411 (2 μM, 1 h) distributes in the nuclei of both MCF-7 and MCF-10A cells, but its cytoplasmic distribution is higher in MCF-7 cells[2].
AS 1411 (10 μM, 72 h) inhibits the stability of Bcl-2 mRNA in MCF-7 and MDA-MB-231 cells, with no effect on MCF-10A cells[2].
AS 1411 (0-10 μM, 72 h) inhibits the binding of nucleoproteins to bcl-2 mRNA in MCF-7 cells[2].
AS 1411 conjugated with gold nanoparticles (0-800 nM, 72 h) exerts a stronger antiproliferative effect on MCF-7 and MDA-MB-231 cells compared to AS 1411 alone, without affecting MCF-10A cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:DU145
-
Concentration:10 μM
-
Incubation Time:24 h
-
Result:Increased the proportion of cells in S phase and decreased G2-M cells.
-
Cell Line:MCF-7, MCF-10A
-
Concentration:0, 5, 10, 20 μM
-
Incubation Time:0, 24, 48, 72, 96 h
-
Result:Inhibited the proliferation of MCF-7 and lost mitochondrial activity after 72 hours, but had no effect on MCF-10A.
-
Cell Line:MCF-7; MDA-MB-231; MCF-10A
-
Concentration:0, 200, 400, 600, 800 nM，
-
Incubation Time:72 h
-
Result:Inhibited MCF-7 cell survival by more than 80% at 200 nM, whereas neither AS1411 alone nor control GNS had a significant effect under these conditions. AS1411GNS (88% cell death at 200 nM) was significantly increased in MDA-MB-231 cells compared to AS1411 (27% cell death at 10 μM).
-
Cell Line:DU145
-
Concentration:10 μM
-
Incubation Time:24 h
-
Result:Increased the mRNA expressions of cyclin E2 and ST7.
-
Cell Line:MCF-7, MCF-10A
-
Concentration:10 μM
-
Incubation Time:72 h
-
Result:Reduced the stability of bcl-2 mRNA, reducing the half-life of bcl-2 from 10h to 1h in MCF-7 cells and from 11h to 1.2h in MDA-MB-231 cells, but had no effect on MCF-10A cells.
-
Cell Line:DU145; DU145 cells transfected with siRNA; NM23
-
Concentration:10 μM
-
Incubation Time:0, 1, 4, 24, 48 h
-
Result:Reduced nucleolar protein-associated PRMT5 in the nucleus of DU145 cells and increased nucleolar protein-associated PRMT5 in the cytoplasm, which was related to time and dose.
Reduced the expression of PRMT5 in DU145 cells, upregulated the expression of PRMT5 cyclin2 and ST7 and inhibited tumor proliferation.
-
Cell Line:MCF-7, MCF-10A
-
Concentration:2 μM
-
Incubation Time:1 h
-
Result:Distributed in the cell nucleus, and its distribution in the cytoplasm of MCF-7 is higher than that of MCF-10A and it is more sensitive to MCF-7.
-
Cell Line:MCF-7
-
Concentration:0, 5, 10 μM
-
Incubation Time:72 h
-
Result:Reduced the enrichment of bcl-2 mRNA in the immunoprecipitate.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female nude mice bearing MDA-MB-231 xenografts[3]
-
Dosage:22 μg; once a day; 12 days
-
Administration:Intravenous injection (i.v.)
-
Result:Took up and retained in tumors and cleared in normal tissues.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 301636-59-9
-
Appearance Solid
-
Molecular Weight 8272.31
-
Color White to off-white
-
SMILES
[AS 1411]
-
Synonyms
AGRO-100
-
Sequence
DNA, d(G-G-T-G-G-T-G-G-T-G-G-T-T-G-T-G-G-T-G-G-T-G-G-T-G-G)
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Phytomedicine
2025 Jun 2:144:156932. PMID: 40482618 -
Int J Pharm X
An aptamer-conjugated mesoporous polydopamine formulation for synergistic targeted and photothermal therapy of hepatocellular carcinoma. [Abstract]2025 Apr 24:9:100335. PMID: 40927752
Purity & Documentation
-
Data Sheet (277 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (1518 KB)
References
[1]. Teng Y, et al. AS1411 alters the localization of a complex containing protein arginine methyltransferase 5 and nucleolin. Cancer Res. 2007;67(21):10491-10500. [Content Brief]
[2]. Soundararajan S, et al. The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells. Cancer Res. 2008;68(7):2358-2365. [Content Brief]
[3]. Mohammad T Malik, et al. AS1411-conjugated gold nanospheres and their potential for breast cancer therapy. Oncotarget. 2015 Sep 8;6(26):22270-81. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz